Collaborating Investigator: Jonathan Powell
Affiliation: Calico

Funding Source: Internal
Project Period: 11/2022-10/2026

Summary

SP#2 investigates metabolic programming of aAPC NP- and MP-stimulated T cells. 

Approach

At Calico, the Powell lab is studying the effects of various metabolic modifiers and genetic targets on T cell fitness. 

TR&D1 will provide SOP and nano-aAPC and MP-technology to the Powell lab to better enable metabolically modified, CD8+ and CD4+ antigen-specific T cells using in vitro stimulation. The aAPC NP and MP platforms will be used for the expansion of tumor-specific CD4+ and CD8+ T cells that are treated with various metabolic modifiers such as DON, AKT inhibitors, and GSK1 inhibitors. These may also include Calico proprietary compounds